82 related articles for article (PubMed ID: 25068470)
1. Use of Hematopoietic Growth Factors in Elderly Lung Cancer Patients Receiving Chemotherapy: A SEER-Medicare-based Study.
Rajan SS; Cai Y; Yi M; Tsai CL; Du XL
Am J Clin Oncol; 2017 Feb; 40(1):66-74. PubMed ID: 25068470
[TBL] [Abstract][Full Text] [Related]
2. Temporal and Geographic Variations in the Receipt of Colony-Stimulating Factors and Erythropoiesis-Stimulating Agents in a Large Retrospective Cohort of Older Women With Breast Cancer From 2000 to 2009.
Du XL; Zhang Y; Hardy D
Am J Ther; 2016; 23(2):e411-21. PubMed ID: 25756469
[TBL] [Abstract][Full Text] [Related]
3. Increasing utilization and predictors of hematopoietic growth factors in patients diagnosed with colorectal cancer: findings from a large national population-based cohort in the USA, 1992-2009.
Zhang Y; Fu SS; Du XL
Med Oncol; 2014 Oct; 31(10):242. PubMed ID: 25231751
[TBL] [Abstract][Full Text] [Related]
4. Associations between hematopoietic growth factors and risks of venous thromboembolism, stroke, ischemic heart disease and myelodysplastic syndrome: findings from a large population-based cohort of women with breast cancer.
Du XL; Zhang Y; Hardy D
Cancer Causes Control; 2016 May; 27(5):695-707. PubMed ID: 27059219
[TBL] [Abstract][Full Text] [Related]
5. Risks of Venous Thromboembolism, Stroke, Heart Disease, and Myelodysplastic Syndrome Associated With Hematopoietic Growth Factors in a Large Population-Based Cohort of Patients With Colorectal Cancer.
Du XL; Zhang Y
Clin Colorectal Cancer; 2015 Dec; 14(4):e21-31. PubMed ID: 26119923
[TBL] [Abstract][Full Text] [Related]
6. Temporal and geographic variation in the use of hematopoietic growth factors in older women receiving breast cancer chemotherapy: findings from a large population-based cohort.
Du XL; Lairson DR; Begley CE; Fang S
J Clin Oncol; 2005 Dec; 23(34):8620-8. PubMed ID: 16314624
[TBL] [Abstract][Full Text] [Related]
7. The effects of erythropoiesis-stimulating agents on the short-term and long-term survivals in metastatic breast cancer patients receiving chemotherapy: a SEER population-based study.
Lai Y; Ye Z; Civan JM; Wang C; Cristofanilli M; Mu Z; Austin L; Palazzo JP; Myers RE; Yang H
Breast Cancer Res Treat; 2015 Sep; 153(2):407-16. PubMed ID: 26264468
[TBL] [Abstract][Full Text] [Related]
8. Use of Hematopoietic Growth Factors and Risk of Thromboembolic and Pulmonary Toxicities in Elderly Patients with Advanced Ovarian Cancer.
Poonawalla IB; Piller LB; Lairson DR; Chan W; Du XL
Womens Health Issues; 2016; 26(5):574-83. PubMed ID: 27365286
[TBL] [Abstract][Full Text] [Related]
9. Predictors of Unplanned Hospitalizations in Patients With Nonmetastatic Lung Cancer During Chemotherapy.
Fessele KL; Hayat MJ; Atkins RL
Oncol Nurs Forum; 2017 Sep; 44(5):E203-E212. PubMed ID: 28820513
[TBL] [Abstract][Full Text] [Related]
10. Colony-stimulating factor use and impact on febrile neutropenia among patients with newly diagnosed breast, colorectal, or non-small cell lung cancer who were receiving chemotherapy.
McCune JS; Sullivan SD; Blough DK; Clarke L; McDermott C; Malin J; Ramsey S
Pharmacotherapy; 2012 Jan; 32(1):7-19. PubMed ID: 22392824
[TBL] [Abstract][Full Text] [Related]
11. Adherence to guidelines for use of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia: results of a retrospective study of an electronic medical-records database in the United States, 2002-2006.
Luo W; Nordstrom BL; Fraeman K; Nordyke R; Ranganathan G; Linz HE; Winterkorn A; Stokes M; Ross SD; Knopf K
Clin Ther; 2008 Dec; 30(12):2423-35. PubMed ID: 19167601
[TBL] [Abstract][Full Text] [Related]
12. Physician characteristics and variability of erythropoiesis-stimulating agent use among Medicare patients with cancer.
Wright JD; Neugut AI; Wilde ET; Buono DL; Malin J; Tsai WY; Hershman DL
J Clin Oncol; 2011 Sep; 29(25):3408-18. PubMed ID: 21810679
[TBL] [Abstract][Full Text] [Related]
13. Trends and predictors of first-line chemotherapy use among elderly patients with advanced non-small cell lung cancer in the United States.
Lang K; Marciniak MD; Faries D; Stokes M; Buesching D; Earle C; Treat J; Morissette N; Thompson D
Lung Cancer; 2009 Feb; 63(2):264-70. PubMed ID: 18649969
[TBL] [Abstract][Full Text] [Related]
14. The Impact of the Risk Evaluation Mitigation Strategy for Erythropoiesis-Stimulating Agents on Their Use and the Incidence of Stroke in Medicare Subjects with Chemotherapy-Induced Anemia with Lung and/or Breast Cancers.
Hollingsworth K; Romney MC; Crawford A; McAna J
Popul Health Manag; 2016 Feb; 19(1):63-9. PubMed ID: 26102512
[TBL] [Abstract][Full Text] [Related]
15. Complications associated with erythropoietin-stimulating agents in patients with metastatic breast cancer: a Surveillance, Epidemiology, and End Results-Medicare study.
Chavez-MacGregor M; Zhao H; Fang S; Srokowski TP; Hortobagyi GN; Giordano SH
Cancer; 2011 Aug; 117(16):3641-9. PubMed ID: 21656514
[TBL] [Abstract][Full Text] [Related]
16. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy.
Lyman GH; Lyman CG; Sanderson RA; Balducci L
J Natl Cancer Inst; 1993 Mar; 85(6):488-93. PubMed ID: 8445677
[TBL] [Abstract][Full Text] [Related]
17. Treatment patterns and burden of myelosuppression for patients with small cell lung cancer: A SEER-medicare study.
Epstein RS; Nelms J; Moran D; Girman C; Huang H; Chioda M
Cancer Treat Res Commun; 2022; 31():100555. PubMed ID: 35421820
[TBL] [Abstract][Full Text] [Related]
18. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
19. Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009.
Dinan MA; Mi X; Reed SD; Lyman GH; Curtis LH
JAMA Oncol; 2015 Nov; 1(8):1098-109. PubMed ID: 26313372
[TBL] [Abstract][Full Text] [Related]
20. Geographic variation and sociodemographic disparity in the use of oxaliplatin-containing chemotherapy in patients with stage III colon cancer.
Panchal JM; Lairson DR; Chan W; Du XL
Clin Colorectal Cancer; 2013 Jun; 12(2):113-21. PubMed ID: 23137529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
